MedTrace Logo

Alpha-lipoic Acid in Diabetic Patients With Ischemic Cardiomyopathy

NCT06056687 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-02-21

No results posted yet for this study

Summary

The aim of this study is to investigate the effect of alpha-lipoic acid on inflammatory markers and cardiac fibrosis markers in diabetic patients with Ischemic Cardiomyopathy.

Conditions

Interventions

DRUG

Alpha Lipoic Acid 600 MG Oral Tablet

Alpha Lipoic Acid 600 MG Oral Tablet once daily

OTHER

Placebo Tablet

Placebo Tablet once daily

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass Prof. · Damanhour University

  • Noha El bassiouny, Lecturer · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-01-31
Completion
2024-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06056687 on ClinicalTrials.gov